<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disseminated gonococcal infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disseminated gonococcal infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Disseminated gonococcal infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey D Klausner, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Disseminated gonococcal infection (DGI) results from bacteremic spread of the sexually transmitted pathogen, <em>Neisseria gonorrhoeae</em>, which can lead to a variety of clinical symptoms and signs, such as arthritis or arthralgias, tenosynovitis, and multiple skin lesions. </p><p>This topic will discuss the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of DGI. The clinical manifestations, diagnosis, and treatment of uncomplicated gonococcal infection (eg, cervicitis and urethritis) are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents"</a> and  <a class="medical medical_review" href="/d/html/15893.html" rel="external">"Clinical manifestations and diagnosis of <i>Neisseria gonorrhoeae </i>infection in adults and adolescents"</a> and  <a class="medical medical_review" href="/d/html/7587.html" rel="external">"Epidemiology and pathogenesis of <i>Neisseria gonorrhoeae</i> infection"</a>.)</p><p class="headingAnchor" id="H16637766"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Disseminated gonococcal infection (DGI) is estimated to occur in 0.5 to 3 percent of patients infected with <em>N. gonorrhoeae</em> [<a href="#rid1">1-3</a>]. </p><p>Most patients with DGI are younger than 40 years of age, although DGI can occur in any age group. Historically, DGI occurred more frequently in females than males; however, that sex ratio may be reversing, with increases in gonococcal infection in general among males, and because DGI might be more common among individuals with HIV (of whom males comprise the majority in North America and Western Europe) [<a href="#rid1">1,4-11</a>].</p><p>DGI is considered a common cause of acute polyarthralgias, polyarthritis, or oligoarthritis in young, otherwise healthy patients. Although <em>Staphylococcus aureus </em>is the most common cause of monomicrobial septic arthritis overall, among sexually active adults, <em>N. gonorrhoeae </em>is the most common causative organism [<a href="#rid12">12</a>]. Nevertheless, the overall proportion of septic arthritis cases that are due to <em>N. gonorrhoeae</em> is low. In case studies from Europe during the 1990s, <em>N. gonorrhoeae </em>was the causative organism in 1.7 percent in a series from France [<a href="#rid13">13</a>], 0.6 percent in a series from the United Kingdom [<a href="#rid14">14</a>], and 0 percent from a three-year prospective community-based study in the Netherlands [<a href="#rid15">15</a>]. In a retrospective study of 34 cases of musculoskeletal infections among intravenous drug users in Spain, <em>N. gonorrhoeae </em>was the causative agent in 2.9 percent [<a href="#rid16">16</a>]. The prevalence of gonococcal arthritis may be higher in the United States than in the United Kingdom [<a href="#rid17">17</a>]. Gonococcal arthritis appears to be more prevalent in more resource-limited settings, although there are limited epidemiologic studies from such regions [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY AND PREDISPOSING FACTORS</span><span class="headingEndMark"> — </span>The probability that a localized gonococcal infection will spread to joints and other tissues depends upon specific host, microbial, and possibly immune factors.</p><p class="headingAnchor" id="H3"><span class="h2">Host factors</span><span class="headingEndMark"> — </span>A history of recent symptomatic genital infection is uncommon in individuals with disseminated gonococcal infection (DGI); asymptomatic mucosal infection is thought to increase the risk of dissemination due to delayed diagnosis, resulting in delays in antibiotic treatment [<a href="#rid6">6,18</a>]. Other risk factors for DGI include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Recent menstruation – The association between menstruation and DGI may be due to several factors [<a href="#rid19">19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Menses is associated with phenotypic changes of <em>N. gonorrhoeae </em>from opaque strains to transparent strains (those with altered membrane protein expression) [<a href="#rid20">20</a>]. Transparent strains may be less sensitive to lysis by trypsin, less adherent to neutrophils [<a href="#rid21">21</a>], and may also be more adherent to fallopian tubes [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genital secretions during menses are more alkaline, which may facilitate gonococcal growth [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased concentrations of transferrin and heme at mucosal surfaces during menstruation may be used as a source of iron by <em>N. gonorrhoeae </em>[<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy or the immediate postpartum state [<a href="#rid25">25,26</a>] – The risk of DGI associated with pregnancy is postulated to result from normal immunological changes during pregnancy, such as alterations in cell-mediated immunity and increased vascularity, which may predispose to <em>N gonorrhoeae </em>invasion [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital or acquired complement deficiencies (C5, C6, C7, or C8) [<a href="#rid27">27,29</a>] – Select complement deficiencies predispose to DGI as a result of decreased complement-mediated killing of <em>N. gonorrhoeae; </em>up to 50 percent of patients with C6, C7, or C8 complement deficiencies may develop bacteremia with pathogenic <em>Neisseria</em> species<em> </em>[<a href="#rid29">29</a>]<em>. </em>Further, among patients with DGI, there is a notable prevalence of complement deficiency, with estimates between 4 and 13 percent [<a href="#rid18">18,30</a>]. Complement deficiencies also predispose to recurrent, and perhaps subacute or even chronic infections [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus (SLE) – SLE may predispose to DGI; however, conflicting reports exist [<a href="#rid32">32,33</a>]. Mechanisms that could potentially explain an association between SLE and DGI include complement depletion as a result of immune complex deposition [<a href="#rid34">34</a>], a possible association between SLE and inherited complement deficiencies [<a href="#rid35">35</a>], and use of immunosuppressive medications [<a href="#rid36">36</a>]. Given that the range of symptoms seen with DGI and SLE flares overlap, a high index of suspicion for DGI is warranted in patients with SLE [<a href="#rid36">36,37</a>]. (See <a class="local">'Clinical suspicion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> – Eculizumab is a monoclonal antibody to C5 that is used in certain conditions, such as complement-mediated hemolytic uremic syndrome, and has been associated with severe meningococcal infections. Theoretically, eculizumab could also increase the risk of DGI given the risk with other acquired complement deficiencies. There have been sporadic reports of DGI among patients treated with eculizumab [<a href="#rid38">38-40</a>]. Between 2004 and 2017, eight such cases were reported to the US Food and Drug Administration from the United States, Canada, and Europe [<a href="#rid40">40</a>]. Seven patients had positive blood cultures. </p><p></p><p class="headingAnchor" id="H4"><span class="h2">Microbial factors</span><span class="headingEndMark"> — </span><em>N. gonorrhoeae</em> contain a variety of virulence and growth factors associated with an increased propensity to cause DGI:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Porins</strong> – Porins are outer membrane structures. Porin B isoform 1A (PorB<sub>1a</sub>) differs from the other existing isoform (PorB<sub>1b</sub>), and the presence of PorB<sub>1a</sub> has been associated with increased serum resistance and a capacity to cause DGI under low-phosphate conditions [<a href="#rid41">41-43</a>]. The exchange of arginine for histidine at locus 92 is highly conserved among PorB<sub>1a</sub> isolates, and not among PorB<sub>1b</sub> isolates; PorB<sub>1b </sub>isolates thus have a serine residue with resulting loss of the invasive phenotype [<a href="#rid44">44</a>]. A proposed mechanism for the increased invasive capacity of PorB<sub>1a</sub> involves regulatory complement factor H (fH) and C4 binding protein with preferential binding to strains expressing PorB<sub>1a</sub>, which correlates with an increased conversion of C3b to iC3b and, thus, decreased complement-mediated killing. Furthermore, fH binds sialylated lipopolysaccharide and is responsible for further inactivation of C3b and alternative pathway-mediated killing [<a href="#rid42">42,45-47</a>]. Additional work has shown that <em>N. gonorrhoeae </em>invades epithelial cells via the scavenger receptor expressed by endothelial cells (SREC-I) in a manner that is dependent on PorB<sub>1a</sub> [<a href="#rid48">48</a>]. That invasion, and potentially a starting point for dissemination, is further dependent on host cell membrane rafts [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Auxotype</strong> – Strains<strong> </strong>of <em>N. gonorrhoeae </em>requiring arginine, hypoxanthine, and uracil (AHU auxotype) have been associated with DGI [<a href="#rid50">50,51</a>]. That association may be due to increased resistance to complement-mediated killing, thus conferring serum resistance. Importantly, strains with that auxotype may be clonal, and thus with varying distributions across the world [<a href="#rid52">52,53</a>]. Additionally, the PorB<sub>1a</sub> isoform is found in most strains with the AHU auxotype [<a href="#rid41">41,54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic island with virulence factors</strong> – A genetic island unique to <em>N. gonorrhoeae </em>has been described, which can exist in different forms. One form contains a gene known as <em>sac-4</em> and a peptidoglycan hydrolase gene (<em>atlA</em>). Isolates with genetic islands containing both <em>sac-4</em> and <em>atlA</em> have been found preferentially in strains that cause dissemination. It is thought that <em>sac-4</em> may augment the ability of <em>N. gonorrhoeae </em>to survive in the blood stream, and <em>atlA </em>may increase DNA exportation facilitating transformation and/or may increase the level of cytotoxic peptidoglycan fragments, potentially augmenting the immune response [<a href="#rid55">55</a>]. Notably, in that study, the presence of <em>sac-4</em> correlated with the AHU auxotype.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colony opacity proteins </strong>– <em>N. gonorrhoeae </em>express colony opacity (OpaCEA) proteins, which bind to carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), resulting in colony formation at mucosal surfaces [<a href="#rid56">56</a>]. CEACAM-3 in particular, however, is expressed on human granulocytes and is responsible for uptake and subsequent destruction of <em>N. gonorrhoeae </em>organisms expressing OpaCEA [<a href="#rid57">57-59</a>]. Analysis of <em>N. gonorrhoeae </em>isolated from patients with disseminated infection revealed expected CEACAM binding, with the exception of CEACAM-3, indicating another potential source for immune evasion [<a href="#rid60">60</a>]. Similarly, another study found that transmigration of the epithelial cell layer by <em>N. gonorrhoeae </em>was limited by Opa protein expression, and that bacteria without Opa proteins expressed were able to invade [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipid A</strong> – Lipid A is a component of lipooligosaccharide (LOS), a potent stimulator of the host immune response; the addition of phosphoethanolamine to lipid A is associated with resistance to innate host serum defenses and to <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pili variation </strong>– Pili are filamentous structures on the surface of <em>Neisseria </em>species. Genetic variation among pili is important for immune evasion and may contribute to tissue tropism [<a href="#rid63">63,64</a>]. Pilin galactosyl transferase (<em>pgtA</em>) can have two forms, one with a poly-G tract, which can undergo phase variation, while the second type does not have poly-G tract and is expressed constitutively without any variation. According to one study, most uncomplicated infections lack the poly-G in <em>pgtA</em>. Isolates with a poly-G tract (ie, those that can undergo phase variation), have been highly associated with DGI [<a href="#rid65">65</a>]. The mechanism by which a phase-variable <em>pgtA </em>gene increases the propensity for dissemination may involve: 1) immune evasion by turning off expression of <em>pgtA</em>, thus reducing antigenic exposure to serum antibodies; 2) increased molecular mimicry of variable <em>pgtA </em>proteins [<a href="#rid65">65</a>]; and 3) microcolony destabilization of local infection [<a href="#rid49">49</a>]. Importantly, a subsequent study in a larger, more diverse set of gonococcal isolates was unable to reproduce those findings [<a href="#rid66">66</a>], thus making the role of <em>pgtA </em>on <em>N. gonorrhoeae </em>dissemination uncertain. Work on porins has postulated that loss of microcolony stabilizing pili via phase variation may favor invasion in a PorB<sub>1a </sub>– SREC-I-dependent manner [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Immune factors</span><span class="headingEndMark"> — </span>The immunopathogenesis of DGI is uncertain. The hypothesis that inflammation rather than direct microbial invasion causes the clinical findings of DGI is supported by the frequent lack of <em>N. gonorrhoeae</em> growth from blood, skin, and synovial fluid cultures during disseminated infection (see <a class="local">'Laboratory and microbiologic testing'</a> below). Fastidious growth requirements of <em>N. gonorrhoeae </em>could explain the sterile cultures, and more sensitive testing methods (such as immunofluorescence or molecular techniques) have identified organisms in synovial and skin samples that were culture negative [<a href="#rid67">67-71</a>]. Nevertheless, persistent synovitis in DGI can occur in culture and PCR-negative joints, and organisms can often be cultured from the genitourinary tract or other local sites in most cases of DGI, despite negative cultures elsewhere [<a href="#rid72">72,73</a>]. Thus, the sterile synovitis, tenosynovitis, and dermatitis associated with DGI may not always require viable <em>N. gonorrhoeae</em>, and other inflammatory mechanisms may be important.</p><p>Immune complex deposition may play a role; however, studies attempting to identify immune complexes among patients with DGI report conflicting results [<a href="#rid74">74-76</a>]. The observation that <em>N. gonorrhoeae</em> cell wall components can induce inflammation and arthritis in animal studies also supports an immune component to DGI [<a href="#rid77">77</a>]. Components of the cell wall and membrane stimulate the immune response and may remain as soluble factors that perpetuate inflammatory mediators with the potential to combat the infection and damage protective mucosa, perhaps facilitating bacterial invasion and dissemination [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2174139947"><span class="h2">Spectrum of findings</span><span class="headingEndMark"> — </span>Most patients with disseminated gonococcal infection (DGI) report feeling well up to the onset of the illness. Upon presentation, a range of clinical findings associated with DGI has been described  (<a class="graphic graphic_table graphicRef56577" href="/d/graphic/56577.html" rel="external">table 1</a>) [<a href="#rid5">5,18</a>]. Those can be divided into two groups: </p><p class="bulletIndent1"><span class="glyph">●</span>A triad of tenosynovitis, dermatitis, and polyarthralgia without purulent arthritis (also called the "arthritis-dermatitis syndrome"). Those findings occur frequently in patients with DGI [<a href="#rid6">6</a>]. (See <a class="local">'Tenosynovitis, dermatitis, polyarthralgia (also called arthritis-dermatitis syndrome)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purulent arthritis with or without associated findings. Fewer than 50 percent of patients with DGI present with actual arthritis [<a href="#rid6">6</a>]. (See <a class="local">'Purulent arthritis'</a> below.)</p><p></p><p>Those two classic forms may represent a spectrum of DGI [<a href="#rid79">79</a>]. Most patients who develop suppurative arthritis have not had preceding polyarthralgia or skin lesions, although patients with the polyarthralgia syndrome can develop purulent arthritis later in the disease course if not recognized and treated [<a href="#rid23">23</a>]. The pathogenic mechanism responsible for the strikingly different clinical presentations is poorly understood, although it may in part depend upon differences in the infecting strain of the organism.</p><p>Patients with either of the above clinical syndromes usually do not simultaneously manifest signs and symptoms of a gonococcal infection involving mucous membranes, even though localized infection of the urethra, cervix, rectum, or pharynx typically precedes the onset of DGI. </p><p>Other manifestations, such as endocarditis [<a href="#rid80">80,81</a>], myopericarditis [<a href="#rid82">82</a>], meningitis [<a href="#rid26">26,83,84</a>], osteomyelitis [<a href="#rid85">85</a>], abscesses [<a href="#rid86">86,87</a>], and vasculitis [<a href="#rid88">88</a>], can also occur. Those can occur either in isolation or in addition to the more typical manifestations of DGI. However, those complications are so rare that they will not be discussed in this topic review.</p><p class="headingAnchor" id="H7"><span class="h2">Tenosynovitis, dermatitis, polyarthralgia (also called arthritis-dermatitis syndrome)</span><span class="headingEndMark"> — </span>This form of DGI generally occurs within two to three weeks of the primary infection and is characterized by the following features [<a href="#rid18">18,89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever, chills, and generalized malaise – These occur in the acute phase of infection. Fever may spontaneously disappear or diminish in magnitude as the disorder progresses, and so is not uniformly observed. As an example, in a study of 112 women with DGI, approximately 60 percent had a temperature &gt;100.4°F (&gt;38°C) on presentation [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyarthralgia – This can involve small or large joints. Several joints can be affected, but symmetric joint involvement is uncommon. A distinguishing feature is the migratory nature of the arthralgias compared with other causes of septic arthritis [<a href="#rid18">18,90</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tenosynovitis – This is a relatively common finding that is unique to DGI and is unusual in other forms of infectious arthritis [<a href="#rid18">18,90</a>]. It often involves multiple tendons simultaneously, particularly at the wrist, fingers, ankle, and toes [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/d/html/7654.html" rel="external">"Infectious tenosynovitis", section on 'Clinical manifestations'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dermatitis – Skin findings are common and occur in approximately 75 percent of cases [<a href="#rid23">23</a>]. Typical lesions are painless, and patients may be unaware of them. Lesions are usually pustular or vesiculopustular  (<a class="graphic graphic_picture graphicRef59399" href="/d/graphic/59399.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef69978" href="/d/graphic/69978.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef71303" href="/d/graphic/71303.html" rel="external">picture 3</a>) [<a href="#rid91">91</a>], although hemorrhagic macules, papules, bullae, or nodules rarely occur. Rarely, patients with DGI can develop lesions that are urticarial or that resemble erythema nodosum or erythema multiforme [<a href="#rid23">23</a>]. It is common to find between 2 and 10 lesions in an individual patient; there are rarely more than 40 lesions. They typically occur on the distal extremities and are rarely present on the face [<a href="#rid23">23</a>]. Pustular or vesicular skin lesions are often transient and often last for only three to four days, even without treatment. (See  <a class="medical medical_review" href="/d/html/15867.html" rel="external">"Cutaneous manifestations of gonorrhea", section on 'Disseminated gonococcal infection'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Purulent arthritis</span><span class="headingEndMark"> — </span>Patients with this form of DGI typically present with abrupt onset of mono- or oligoarthritis, with pain and swelling in one or more joints. Gonococcal arthritis generally involves distal joints, with knees, wrists, and ankles the most commonly involved joints [<a href="#rid6">6,23</a>]. Axial involvement is rare, although cases with glenohumeral joint and sternoclavicular joint involvement have been reported [<a href="#rid25">25,85,92-96</a>]. Polyarthritis, when present, is typically asymmetric. Most patients are afebrile. </p><p>As noted above, a small number of patients with purulent arthritis may also have tenosynovitis or skin lesions. (See <a class="local">'Tenosynovitis, dermatitis, polyarthralgia'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H1863085819"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The possibility of disseminated gonococcal infection (DGI) should be considered in sexually active individuals (particularly those younger than 40 years, those with multiple partners, and all men who have sex with men) who present with arthralgias or joint pain concerning for septic arthritis. A low threshold for suspicion is important since not all patients will report sexual activity, and DGI has been reported in older adults [<a href="#rid97">97</a>], whom providers may assume not to be sexually active. </p><p>Accompanying skin lesions, particularly pustular or vesiculopustular lesions, and/or tenosynovitis (tenderness along the flexor sheath or pain with passive extension) should heighten suspicion for DGI. </p><p>Given that the range of symptoms seen with DGI and systemic lupus erythematosus (SLE) flares overlap and that some reports suggest an increased risk of DGI among patients with SLE, a high index of suspicion for DGI is warranted in patients with SLE.</p><p class="headingAnchor" id="H10"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>Patients suspected of having DGI should undergo a complete history and physical examination. In addition to evaluating for the typical clinical manifestations of joint involvement with or without skin findings discussed above (see <a class="local">'Clinical manifestations'</a> above), a thorough sexual history should be performed. Most patients with DGI have a history of recent sexual activity, although this may not be elicited in all, which highlights the importance of patient-provider trust and a nonjudgmental attitude. Furthermore, only a minority of patients report having recently had a sexually transmitted infection (STI), but some may report a more remote STI diagnosis. Among women, the timing of the last menstrual period and the possibility of pregnancy should be assessed. </p><p>A careful physical examination is often needed to detect the characteristic skin lesions of DGI  (<a class="graphic graphic_picture graphicRef59399" href="/d/graphic/59399.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef69978" href="/d/graphic/69978.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef71303" href="/d/graphic/71303.html" rel="external">picture 3</a>). Typical lesions may be mistakenly dismissed as unimportant furuncles or pimples by the patient or clinician. (See  <a class="medical medical_review" href="/d/html/15867.html" rel="external">"Cutaneous manifestations of gonorrhea", section on 'Disseminated gonococcal infection'</a>.)</p><p>Careful evaluation of the joints is also important. It is not unusual to see patients with only one or two joints that are involved. Small or large joints may be affected, and symmetric joint involvement is uncommon [<a href="#rid92">92</a>]. Tenosynovitis is often visible to the examining clinician, with redness and warmth along the tendon sheath. Its presence can usually be confirmed by eliciting pain along the tendon sheath with active or passive joint movement.</p><p>In addition, signs suggestive of rare DGI complications, such as meningitis or endocarditis should be sought, with further testing (eg, lumbar puncture or echocardiography) in patients with concerning findings on exam. (See  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p>The general approach to history and physical examination in patients with joint pain is discussed in further detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1821.html" rel="external">"Evaluation of the adult with polyarticular pain", section on 'History'</a> and  <a class="medical medical_review" href="/d/html/1821.html" rel="external">"Evaluation of the adult with polyarticular pain", section on 'Physical signs'</a>.)</p><p class="headingAnchor" id="H1071546224"><span class="h2">Laboratory and microbiologic testing</span><span class="headingEndMark"> — </span>Several specimens are collected for testing in patients with suspected DGI; culture of blood, synovial fluid, and skin lesions are frequently negative.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood cultures</strong> – At least two sets of blood cultures should be obtained. Cultures are diagnostic when positive and are also helpful in separating DGI from other conditions, such as septic arthritis due to <em>Neisseria meningitidis</em> or <em>S. aureus</em>, both of which may mimic the clinical features of DGI. The reported frequency of blood culture positivity in various case series ranges from 4 to 70 percent of cases [<a href="#rid4">4,18,98,99</a>]. Patients with the tenosynovitis, dermatitis, and polyarthralgia form of DGI may be more likely to have positive blood cultures, as such symptoms may reflect an earlier, bacteremic stage of disease [<a href="#rid18">18,99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specimens from mucosal sites</strong> – Patients with the clinical features of DGI should have urogenital, rectal, and pharyngeal specimens submitted for microbiologic testing for <em>N. gonorrhoeae. </em>Often, patients with DGI have evidence of infection at urogenital, rectal, or pharyngeal sites despite lack of symptoms at these sites [<a href="#rid4">4,23</a>]. Nucleic acid amplification testing (NAAT) is the preferred diagnostic test [<a href="#rid100">100</a>]. If culture is used, any specimens submitted for culture should be processed on Thayer-Martin media. The optimal urogenital specimen depends on the type of testing performed. Urine (for men) and self-collected vaginal swabs (for women) are the preferred specimens for NAAT, and urethral and cervical swabs are the preferred specimens for culture. (See  <a class="medical medical_review" href="/d/html/15893.html" rel="external">"Clinical manifestations and diagnosis of <i>Neisseria gonorrhoeae </i>infection in adults and adolescents", section on 'Diagnostic techniques'</a>.)</p><p></p><p class="bulletIndent1">If associated urethritis is simultaneously present, a Gram stain of the urethral exudate should be obtained and examined for the presence of the gram-negative diplococci characteristic of <em>N. gonorrhoeae</em> infection. (See  <a class="medical medical_review" href="/d/html/86698.html" rel="external">"Urethritis in adult males", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Synovial fluid</strong> – Synovial fluid should be sent for analysis in all patients with suspected DGI who have an accessible joint effusion. Synovial fluid is generally sent for cell count, differential, Gram stain, and bacterial culture, and the laboratory should be alerted that gonococcal infection is a consideration so that the specimen can be processed and plated appropriately. For those with purulent arthritis, cultures for <em>N. gonorrhoeae</em> may only be positive in approximately 50 percent of cases or less [<a href="#rid4">4,18,98</a>]. Cultures are even less likely to be positive for those who present with the tenosynovitis, dermatitis, and polyarthralgia, even if synovial fluid can be obtained. NAAT appears more sensitive than culture of synovial fluid in patients with gonococcal arthritis [<a href="#rid68">68,69</a>], and should also be performed if available. However, in certain settings, even if available for other specimens, NAAT may not be verified for use on synovial fluid. </p><p></p><p class="bulletIndent1">The mean synovial fluid leukocyte count in septic arthritis is typically around 50,000 cells/microL [<a href="#rid101">101,102</a>]; in some cases of gonococcal arthritis, however, lower counts can be observed (approximately 20,000 cells/microL)  (<a class="graphic graphic_table graphicRef76506" href="/d/graphic/76506.html" rel="external">table 2</a>). Chemistry studies of the joint fluid, such as the concentrations of glucose, lactate dehydrogenase (LDH), or protein, have only limited value; a reduction in glucose concentration and elevation of LDH are consistent with a bacterial infection but are not diagnostic or particularly sensitive [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/1828.html" rel="external">"Synovial fluid analysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin lesion specimens</strong> – Laboratory testing of skin lesion samples is not typically part of the workup for DGI. Many associated skin lesions are not amenable to drainage and sampling. If pustular skin lesions are present, specimens from these lesions can be sent for Gram stain and gonococcal culture, but the yield of these is often low; in one study, culture was positive in 10 percent [<a href="#rid98">98</a>]. NAAT has also been used successfully on skin specimens [<a href="#rid71">71</a>], but this test may not be widely available for this type of specimen.</p><p></p><p>If <em>N. gonorrhoeae</em> is isolated on culture from any specimen, antimicrobial susceptibility testing should also be performed.</p><p class="headingAnchor" id="H4007538143"><span class="h2">Screening for other sexually transmitted infections</span><span class="headingEndMark"> — </span>In addition, all patients with known or suspected DGI should undergo testing for other sexually transmitted infections, such as HIV infection, hepatitis B infection, <em>Chlamydia trachomatis</em>, and syphilis, since coexistent infection with other sexually transmitted pathogens is common. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H4225310951"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The definite diagnosis of disseminated gonococcal infection is made by identification of <em>N. gonorrhoeae</em> (either through nucleic acid testing or culture) on a specimen of blood, synovial fluid or tissue, skin lesion, or other non-mucosal site. If those specimens are negative, the presumptive diagnosis can be made in a patient with microbiologic evidence of <em>N. gonorrhoeae</em> from mucosal (urogenital, rectal, or pharyngeal) specimens and a clinical presentation consistent with disseminated infection. </p><p>In cases where all microbiologic tests are negative, the diagnosis is assumed based on a consistent clinical presentation, absence of alternative cause, and response to appropriate therapy.</p><p class="headingAnchor" id="H13"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>An array of other infectious and noninfectious diseases may mimic disseminated gonococcal infection (DGI). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Septic arthritis</strong> – Acute purulent arthritis due to other bacteria (such as <em>S. aureus</em>) can occur in young, sexually active patients, particularly if they have underlying risk factors, such as injection drug use. Those infections may present with monoarthritis or oligoarthritis, fever, and chills. Identification of an organism on bacterial culture of synovial fluid should distinguish those infections from DGI. (See  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a>.)</p><p></p><p class="bulletIndent1">Primary purulent arthritis caused by <em>N. meningitidis</em> is uncommon [<a href="#rid104">104-106</a>], but its presentation may be near identical to that of DGI, and the organisms cannot be differentiated on Gram stain. However, meningococcal infection is usually a more severe disease than DGI, and most patients with meningococcal arthritis also have clinical signs of sepsis or concurrent meningitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexually transmitted infections</strong> – Patients with suspected DGI should be considered at risk for other sexually transmitted infections (STIs), some of which can present with similar symptoms. Since those STIs can coexist with DGI, STI screening should be performed even if the diagnosis has been established. (See <a class="local">'Screening for other sexually transmitted infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis B virus (HBV) infection</strong> – Patients with acute HBV infection may develop fever, chills, polyarthritis, tenosynovitis, and rash. However, the associated rash is typically urticarial, and synovial fluid analysis usually shows noninflammatory fluid. Furthermore, the arthritis associated with HBV is more often polyarticular and symmetric. In addition to those clinical features, patients with HBV infection can usually be distinguished from those with DGI by the presence of elevated serum aminotransaminases and evidence of acute HBV infection on serologic testing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HIV</strong> – Patients with acute HIV infection can develop rash, fever, chills, and arthralgias. However, joint effusions are uncommon in acute HIV infection, the rash is usually generalized, and mucous membrane involvement is often a dominant finding. All patients with suspected DGI should also be tested for HIV infection. (See  <a class="medical medical_review" href="/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Syphilis</strong> – Secondary syphilis may occasionally be confused with DGI. However, the rash of secondary syphilis usually consists of generalized, maculopapular lesions. Involvement of the palms and soles and generalized lymphadenopathy are also clues to the presence of syphilis. (See  <a class="medical medical_review" href="/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Herpes simplex virus (HSV)</strong> – Primary HSV infection with genital and extragenital lesions can mimic the skin lesions that occur in DGI [<a href="#rid107">107</a>]. Those can be distinguished by direct viral testing of the lesions. (See  <a class="medical medical_review" href="/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mpox</strong> – In the context of the 2022 global mpox (previously referred to as monkeypox) outbreak, in which person-to-person transmission among men who have sex with men has been a primary means of infection, individuals at risk for DGI may also be at risk for mpox. The prodromal systemic symptoms and skin lesions associated with mpox are similar to those that can occur with DGI. The possibility of mpox should be suspected in individuals being evaluated or treated for DGI because of skin lesions if they have a potential epidemiologic link to mpox (eg, through travel, direct exposure, or potential exposure through a social network) or if they do not respond to empiric therapy for DGI (or other STIs) [<a href="#rid108">108</a>]. Clinical suspicion and evaluation for mpox are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/139254.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of mpox (monkeypox)", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other infections</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with infective endocarditis may present with myalgias, arthralgias, fever, chills, and back pain symptoms that are possible to confuse with DGI. However, most patients with infective endocarditis have prominent cardiac abnormalities, and the majority have blood cultures positive for the infecting organism. (See  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A number of viral infections, including parvovirus B19, measles, rubella, and arboviral infections (eg, chikungunya, dengue and Zika viruses), can also cause rash and arthritis. They can usually be distinguished from DGI by the epidemiologic setting, the character and evolution of the rash, and the presence of other associated findings. Those are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5614.html" rel="external">"Viral arthritis: Causes and approach to evaluation and management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early Lyme disease, with its characteristic erythema chronicum migrans rash, can often be differentiated from DGI by other clinical characteristics and the timing of the appearance and evolution of the rash. A monoarthritis can be seen in late Lyme disease, and serologic testing can help confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/7894.html" rel="external">"Musculoskeletal manifestations of Lyme disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other arthritides</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute rheumatic fever (poststreptococcal arthritis) may present with polyarthritis and rash in young adults. However, the rash of acute rheumatic fever is quite rarely seen, and if observed, it is usually transient and virtually never pustular or vesiculopustular. The diagnosis of acute rheumatic fever is based upon a constellation of findings that include microbiologic or serologic evidence of a recent streptococcal infection and the presence of carditis or neurologic symptoms. Most patients with poststreptococcal arthritis have a characteristically rapid response to salicylates or other anti-inflammatory drugs. (See  <a class="medical medical_review" href="/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reactive arthritis, rheumatoid arthritis, and psoriatic arthritis may be confused with DGI  (<a class="graphic graphic_table graphicRef72238" href="/d/graphic/72238.html" rel="external">table 3</a>). In particular, DGI might be suspected in patients with the constellation of reactive arthritis, tenosynovitis, and urethritis, but unlike with typical DGI, such patients also often have one or more of the following: conjunctivitis, circinate balanitis, or keratoderma blenorrhagicum. Clinical and radiologic evidence of sacroiliitis is also very suggestive of reactive arthritis or spondyloarthritis. In addition, a therapeutic trial of antibiotics can help to differentiate between those disorders. Patients with reactive arthritis characteristically do not respond to treatment for <em>N. gonorrhoeae</em>, whereas response to treatment in DGI is usually rapid and unequivocal. (See  <a class="medical medical_review" href="/d/html/7794.html" rel="external">"Reactive arthritis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gout and other crystal-induced forms of arthritis may cause an acute monoarthritis with fever and chills. That form of monoarthritis is usually distinguished from DGI by synovial fluid analysis and the epidemiologic setting. (See  <a class="medical medical_review" href="/d/html/1667.html" rel="external">"Clinical manifestations and diagnosis of gout"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lupus arthritis can have a similar presentation to that of gonococcal arthritis [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Controlled trials evaluating the treatment regimens and duration of disseminated gonococcal infection (DGI) have not been performed. Management recommendations are extrapolated from treatment studies on uncomplicated gonorrhea and based on expert opinion. Initial management in the inpatient setting and in consultation with an expert in infectious diseases is strongly advised [<a href="#rid109">109</a>]. Because of the increasing problem of antimicrobial-resistant gonococcal infections, specimens for microbiologic testing should be collected prior to antimicrobial treatment. (See <a class="local">'Laboratory and microbiologic testing'</a> above.) </p><p>As with other gonococcal infections, treatment of DGI has evolved over time because of emergent antibiotic resistance [<a href="#rid4">4,52,110-112</a>]. (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Antibiotic resistance'</a>.)</p><p class="headingAnchor" id="H223292"><span class="h2">Initial antimicrobial therapy</span><span class="headingEndMark"> — </span>Parenteral therapy with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> 1 g intravenously every 24 hours is our preferred initial regimen for DGI. Ceftriaxone can also be administered intramuscularly, if necessary, but for patients with purulent arthritis, most experts typically administer ceftriaxone intravenously. Presumptive treatment for chlamydia is also given at the same time unless chlamydial coinfection has been excluded. (See <a class="local">'Treatment of Chlamydia coinfection'</a> below.)</p><p>The duration of therapy depends on the specific clinical syndrome, as discussed below. (See <a class="local">'Definitive therapy and duration'</a> below.)</p><p>Alternatives to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> include intravenous <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> and ceftizoxime, each given as a 1 g dose every eight hours. </p><p>These treatment regimens are consistent with recommendations from the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid109">109</a>].</p><p>Agents other than third-generation cephalosporins are less useful given the widespread resistance of <em>N. gonorrhoeae</em> to various drug classes. Decreased susceptibility of <em>N. gonorrhoeae</em> to the oral third-generation cephalosporin <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> and clinical treatment failures have been reported in Asia and Canada [<a href="#rid113">113-115</a>]. Thus, oral cefixime should only be used with caution for initial therapy. The issue of drug resistance is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Antibiotic resistance'</a>.)</p><p class="headingAnchor" id="H3592023542"><span class="h2">Definitive therapy and duration</span></p><p class="headingAnchor" id="H960077980"><span class="h3">Tenosynovitis, dermatitis, polyarthralgia</span><span class="headingEndMark"> — </span>Patients with the triad of tenosynovitis, dermatitis, and arthralgia or synovitis, who have small or absent joint effusions, typically respond dramatically and quickly to treatment. We agree with the United States Centers for Disease Control and Prevention guidelines to continue antibiotic therapy for at least seven days as long as the clinical signs of infection are gone or nearly gone [<a href="#rid109">109</a>]. Once initial clinical improvement with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> 1 g daily (or one of the alternative initial therapies discussed above) is noted for 24 to 48 hours, the treatment course can be completed with intramuscular ceftriaxone (500 mg for individuals &lt;150 kg or 1 g for individuals ≥150 kg) every 24 hours. </p><p>If susceptibility testing demonstrates full sensitivity to <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>, patients who lack septic arthritis and who respond promptly to parenteral therapy can complete their seven-day course of therapy with oral cefixime (400 mg twice daily) [<a href="#rid23">23,109</a>]. Alternately, in cases in which an isolate of <em>N. gonorrhoeae</em> has been identified and susceptibility to fluoroquinolones, penicillin, and/or <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> has been demonstrated, oral therapy with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 mg twice daily), <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> (500 mg four times daily), or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily) can also be used. However, many labs do not have the capability to perform <em>N. gonorrhoeae</em> culture and susceptibility testing. In the absence of such testing, the course should be completed with a parenteral cephalosporin. (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Antibiotic resistance'</a>.)</p><p class="headingAnchor" id="H1697571200"><span class="h3">Purulent arthritis</span><span class="headingEndMark"> — </span>We generally treat patients with purulent arthritis with intravenous <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (or one of the alternative initial therapies discussed above) until there is good evidence of response (eg, improvement in joint pain and effusion) (see <a class="local">'Initial antimicrobial therapy'</a> above). Clinical improvement and cure of purulent arthritis often require at least 7 to 14 days of parenteral therapy. The precise duration of treatment depends on the overall health status of the patient, including the presence of an immunocompromising condition and the rate of response to therapy. A duration longer than 14 days is appropriate for those with such comorbidities or slow rate of response. </p><p>Patients with purulent arthritis should generally also undergo joint drainage. That can be accomplished either with repeated needle aspirations or arthroscopically. Open surgical or arthroscopic drainage should be utilized for patients in whom needle aspirate is not successful or adequate (as assessed by continuing effusions, leukocytosis, fever, or severe joint pain). (See  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a>.)</p><p class="headingAnchor" id="H3559728205"><span class="h2">Patients with beta-lactam allergy</span><span class="headingEndMark"> — </span>Because of the lack of alternate effective agents for <em>N. gonorrhoeae</em>, it is important to overcome potential barriers to administration of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (or an alternative parenteral cephalosporin).</p><p>Many patients with a history of an IgE-mediated penicillin allergy can use a <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or other third-generation cephalosporins safely, in some cases with skin testing or graded challenge (test dosing). This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a>.)</p><p>Those patients with a documented IgE-mediated hypersensitivity reaction to beta-lactams that would otherwise preclude the use of a third-generation parenteral cephalosporin should undergo desensitization to allow its administration.</p><p>For patients who have other serious, non-IgE-mediated reactions that would preclude the use of a third-generation parenteral cephalosporin (eg, Stevens-Johnson syndrome), consultation with an infectious diseases specialist is warranted. </p><p class="headingAnchor" id="H1618330066"><span class="h1">OTHER MANAGEMENT ISSUES</span></p><p class="headingAnchor" id="H23"><span class="h2">Treatment of Chlamydia coinfection</span><span class="headingEndMark"> — </span>If concurrent <em>C. trachomatis</em> infection has not been excluded with nucleic acid testing, presumptive treatment for chlamydia should be given at the same time as treatment for <em>N. gonorrhoeae</em>. We agree with United States Centers for Disease Control and Prevention (CDC) recommendations to use <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily for seven days) for presumptive treatment of chlamydia in nonpregnant individuals with gonococcal infection [<a href="#rid116">116</a>]. This is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Presumptive treatment for chlamydia'</a> and  <a class="medical medical_review" href="/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection"</a>.) </p><p class="headingAnchor" id="H24"><span class="h2">Partner management</span><span class="headingEndMark"> — </span>Optimal patient management includes ensuring that a patient’s recent sex partners are treated for gonorrhea. Whenever possible, partners who have had sexual contact with patients with disseminated gonococcal infection (DGI) within the 60 days prior to diagnosis should be contacted, offered testing, and be presumptively treated for <em>N. gonorrhoeae</em>. Treatment consists of a single intramuscular dose of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (500 mg for individuals &lt;150 kg or 1 g for individuals ≥150 kg) [<a href="#rid116">116</a>]. If chlamydia coinfection has not been excluded in the patient, sex partners should also be treated for chlamydia. (See <a class="local">'Treatment of Chlamydia coinfection'</a> above.)</p><p><a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">Cefixime</a> 800 mg orally through expedited partner treatment (in addition to presumptive therapy for chlamydia if not excluded in the patient) is an alternative when parental <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is not feasible. (See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Management of sexual partners'</a>.) </p><p class="headingAnchor" id="H1317689135"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Data are limited regarding the prognosis of gonococcal arthritis or DGI. With the early identification of infection and the timely initiation of treatment, the prognosis is generally excellent with few or no long-term sequelae. </p><p class="headingAnchor" id="H25"><span class="h1">RECURRENT INFECTION</span><span class="headingEndMark"> — </span>Patients who have more than one episode of disseminated gonococcal infection should be screened for the presence of a deficiency in one of the terminal components of complement by obtaining an assay for total hemolytic complement activity [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system", section on 'Complement measurement'</a>.)</p><p class="headingAnchor" id="H1774060743"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H16637758"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Disseminated gonococcal infection (DGI) results from bacteremic spread of the sexually transmitted pathogen, <em>Neisseria gonorrhoeae</em>. DGI usually presents as one of two syndromes (see <a class="local">'Clinical manifestations'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A triad of tenosynovitis, dermatitis, and polyarthralgias without frank arthritis – These patients often have systemic symptoms such as fever, chills, and malaise.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Purulent arthritis alone – The knees, wrists, or ankles are usually involved without any systemic symptoms. When present, polyarthritis is typically asymmetric. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion</strong> – The possibility of DGI should be considered in individuals (particularly those younger than 40 years or sexually active with multiple partners) who present with acute polyarthralgias, polyarthritis, or joint pain concerning for septic arthritis. Accompanying skin lesions, particularly pustular or vesiculopustular lesions and/or tenosynovitis (tenderness along the tendon sheath or pain with passive or active joint movement), should heighten suspicion for DGI. Most patients do not have a recent history of urogenital gonorrhea. (See <a class="local">'Clinical suspicion'</a> above and <a class="local">'History and physical examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiologic evaluation</strong> – Patients with clinical features of DGI should have blood cultures performed and synovial, skin, rectal, pharyngeal, and urethral or cervical specimens submitted for microbiological testing. Nucleic acid amplification tests (NAATs) are the preferred diagnostic tests for mucosal specimens (urogenital, rectal, and pharyngeal) and may be more sensitive than culture on synovial fluid. Specimens submitted for gonococcal culture should be processed on specific (Thayer-Martin) media. (See <a class="local">'Laboratory and microbiologic testing'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> –The diagnosis is made by identification of <em>N. gonorrhoeae</em> (either through nucleic acid testing or culture) in a nonmucosal site (blood, synovial fluid, skin). If microbiologic tests are positive only at mucosal sites, the diagnosis is also made if the clinical presentation is consistent with disseminated infection. If all microbiologic tests are negative, the diagnosis is assumed based on a consistent clinical presentation and response to appropriate therapy. All patients with DGI should be tested for HIV infection, hepatitis B infection, syphilis, and chlamydia. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Screening for other sexually transmitted infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – For initial therapy of DGI, we suggest <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 g intravenously [or, if needed, intramuscularly] every 24 hours) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients without septic arthritis, treatment is generally continued for seven days; once clinical improvement has occurred, the course can be completed either with a lower dose of ceftriaxone (500 mg intramuscularly daily as long as the patient weight is &lt;150 kg) or, if susceptibility testing was performed, with an active oral agent. Patients with septic arthritis usually require ceftriaxone for 7 to 14 days along with joint drainage. (See <a class="local">'Initial antimicrobial therapy'</a> above and <a class="local">'Definitive therapy and duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chlamydia coinfection</strong> – <em>Chlamydia trachomatis </em>is a frequent copathogen with <em>N. gonorrhoeae </em>and should be empirically treated if not specifically excluded with microbiologic testing. (See <a class="local">'Treatment of Chlamydia coinfection'</a> above and  <a class="medical medical_review" href="/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Doxycycline as preferred agent'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partner management</strong> – All sex partners within the past 60 days of patients with DGI should be notified and offered treatment for gonococcal infection. (See <a class="local">'Partner management'</a> above.)</p><p></p><p class="headingAnchor" id="H2342574852"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lao-Tzu Allan-Blitz, MD, who contributed to a revision of this topic review. The UpToDate editorial staff also acknowledges Daniel Sexton, MD, and Don Goldenberg, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barr J, Danielsson D. Septic gonococcal dermatitis. Br Med J 1971; 1:482.</a></li><li><a class="nounderline abstract_t">Tuttle CS, Van Dantzig T, Brady S, et al. The epidemiology of gonococcal arthritis in an Indigenous Australian population. Sex Transm Infect 2015; 91:497.</a></li><li><a class="nounderline abstract_t">Noble RC, Reyes RR, Parekh MC, Haley JV. Incidence of disseminated gonococcal infection correlated with the presence of AHU auxotype of Neisseria gonorrhoeae in a community. Sex Transm Dis 1984; 11:68.</a></li><li><a class="nounderline abstract_t">Belkacem A, Caumes E, Ouanich J, et al. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011. Sex Transm Infect 2013; 89:613.</a></li><li><a class="nounderline abstract_t">Bleich AT, Sheffield JS, Wendel GD Jr, et al. Disseminated gonococcal infection in women. Obstet Gynecol 2012; 119:597.</a></li><li><a class="nounderline abstract_t">Bardin T. Gonococcal arthritis. Best Pract Res Clin Rheumatol 2003; 17:201.</a></li><li><a class="nounderline abstract_t">Saraux A, Taelman H, Blanche P, et al. HIV infection as a risk factor for septic arthritis. Br J Rheumatol 1997; 36:333.</a></li><li><a class="nounderline abstract_t">Maharaj R, Mody GM. The rarity of gonococcal arthritis in association with HIV infection. J Infect Dev Ctries 2014; 8:1222.</a></li><li><a class="nounderline abstract_t">Sena Corrales G, Mora Navas L, Palacios Muñoz R, et al. Gonococcal arthritis in human immunodeficiency virus-infected patients. Review of the literature. Reumatol Clin 2017; 13:39.</a></li><li><a class="nounderline abstract_t">Zalavras CG, Dellamaggiora R, Patzakis MJ, et al. Septic arthritis in patients with human immunodeficiency virus. Clin Orthop Relat Res 2006; 451:46.</a></li><li><a class="nounderline abstract_t">Shaw JW, Flegg P, Sweeney J. Gonococcal tenosynovitis in two HIV-infected heterosexual men: delayed diagnoses following negative urine nucleic acid amplification testing. Int J STD AIDS 2016; 27:490.</a></li><li><a class="nounderline abstract_t">Wang DA, Tambyah PA. Septic arthritis in immunocompetent and immunosuppressed hosts. Best Pract Res Clin Rheumatol 2015; 29:275.</a></li><li><a class="nounderline abstract_t">Le Dantec L, Maury F, Flipo RM, et al. Peripheral pyogenic arthritis. A study of one hundred seventy-nine cases. Rev Rhum Engl Ed 1996; 63:103.</a></li><li><a class="nounderline abstract_t">Ryan MJ, Kavanagh R, Wall PG, Hazleman BL. Bacterial joint infections in England and Wales: analysis of bacterial isolates over a four year period. Br J Rheumatol 1997; 36:370.</a></li><li><a class="nounderline abstract_t">Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum 1997; 40:884.</a></li><li><a class="nounderline abstract_t">Belzunegui J, Rodríguez-Arrondo F, González C, et al. Musculoskeletal infections in intravenous drug addicts: report of 34 cases with analysis of microbiological aspects and pathogenic mechanisms. Clin Exp Rheumatol 2000; 18:383.</a></li><li><a class="nounderline abstract_t">Hook EW. Septic gonococcal arthritis is much more common in the USA than in the UK. Br J Rheumatol 1990; 29:283.</a></li><li><a class="nounderline abstract_t">O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore) 1983; 62:395.</a></li><li><a class="nounderline abstract_t">Britigan BE, Cohen MS, Sparling PF. Gonococcal infection: a model of molecular pathogenesis. N Engl J Med 1985; 312:1683.</a></li><li><a class="nounderline abstract_t">James JF, Swanson J. Studies on gonococcus infection. XIII. Occurrence of color/opacity colonial variants in clinical cultures. Infect Immun 1978; 19:332.</a></li><li><a class="nounderline abstract_t">Lambden PR, Heckels JE, James LT, Watt PJ. Variations in surface protein composition associated with virulence properties in opacity types of Neisseria gonorrhoeae. J Gen Microbiol 1979; 114:305.</a></li><li><a class="nounderline abstract_t">Draper DL, Donegan EA, James JF, et al. In vitro modeling of acute salpingitis caused by Neisseria gonorrhoeae. Am J Obstet Gynecol 1980; 138:996.</a></li><li><a class="nounderline abstract_t">Rice PA. Gonococcal arthritis (disseminated gonococcal infection). Infect Dis Clin North Am 2005; 19:853.</a></li><li><a class="nounderline abstract_t">Mickelsen PA, Sparling PF. Ability of Neisseria gonorrhoeae, Neisseria meningitidis, and commensal Neisseria species to obtain iron from transferrin and iron compounds. Infect Immun 1981; 33:555.</a></li><li><a class="nounderline abstract_t">O'Leary AJ, Tejura H, Latibeaudiere M, Edwards G. Gonorrhoea infection presenting in pregnancy with septic arthritis of the sternoclavicular joint. J Obstet Gynaecol 2006; 26:373.</a></li><li><a class="nounderline abstract_t">Burgis JT, Nawaz H 3rd. Disseminated gonococcal infection in pregnancy presenting as meningitis and dermatitis. Obstet Gynecol 2006; 108:798.</a></li><li><a class="nounderline abstract_t">Phupong V, Sittisomwong T, Wisawasukmongchol W. Disseminated gonococcal infection during pregnancy. Arch Gynecol Obstet 2005; 273:185.</a></li><li><a class="nounderline abstract_t">Khoo CL, Davies AJ, Dobson CM, et al. Disseminated gonococcal infection in pregnancy. J Obstet Gynaecol 2009; 29:550.</a></li><li><a class="nounderline abstract_t">Petersen BH, Lee TJ, Snyderman R, Brooks GF. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann Intern Med 1979; 90:917.</a></li><li><a class="nounderline abstract_t">Ellison RT 3rd, Curd JG, Kohler PF, et al. Underlying complement deficiency in patients with disseminated gonococcal infection. Sex Transm Dis 1987; 14:201.</a></li><li><a class="nounderline abstract_t">Davido B, Dinh A, Lagrange A, et al. Chronic gonococcal arthritis with C5 deficiency presenting with brief flare-ups: case study and literature review. Clin Rheumatol 2014; 33:1351.</a></li><li><a class="nounderline abstract_t">Wise CM, Morris CR, Wasilauskas BL, Salzer WL. Gonococcal arthritis in an era of increasing penicillin resistance. Presentations and outcomes in 41 recent cases (1985-1991). Arch Intern Med 1994; 154:2690.</a></li><li><a class="nounderline abstract_t">Mitchell SR, Nguyen PQ, Katz P. Increased risk of neisserial infections in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20:174.</a></li><li><a class="nounderline abstract_t">Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002; 4 Suppl 3:S279.</a></li><li><a class="nounderline abstract_t">Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 1984; 63:243.</a></li><li><a class="nounderline abstract_t">Dutertre M, Tomasevic D, Guillermin Y, et al. Gonococcemia mimicking a lupus flare in a young woman. Lupus 2014; 23:81.</a></li><li><a class="nounderline abstract_t">Hahn A, Ting TV, Taylor J, Frenck RW Jr. Polyarthritis in a 19-year-old female with systemic lupus erythematosus. Clin Pediatr (Phila) 2013; 52:991.</a></li><li><a class="nounderline abstract_t">Hublikar S, Maher WE, Bazan JA. Disseminated gonococcal infection and eculizumab--a "high risk" connection? Sex Transm Dis 2014; 41:747.</a></li><li><a class="nounderline abstract_t">Gleesing J, Chiwane S, Rongkavilit C. Gonococcal septic shock associated with eculizumab treatment. Pediatr Infect Dis J 2012; 31:543.</a></li><li><a class="nounderline abstract_t">Crew PE, Abara WE, McCulley L, et al. Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series. Clin Infect Dis 2019; 69:596.</a></li><li><a class="nounderline abstract_t">Bohnhoff M, Morello JA, Lerner SA. Auxotypes, penicillin susceptibility, and serogroups of Neisseria gonorrhoeae from disseminated and uncomplicated infections. J Infect Dis 1986; 154:225.</a></li><li><a class="nounderline abstract_t">Ram S, Cullinane M, Blom AM, et al. Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med 2001; 193:281.</a></li><li><a class="nounderline abstract_t">Kühlewein C, Rechner C, Meyer TF, Rudel T. Low-phosphate-dependent invasion resembles a general way for Neisseria gonorrhoeae to enter host cells. Infect Immun 2006; 74:4266.</a></li><li><a class="nounderline abstract_t">Zeth K, Kozjak-Pavlovic V, Faulstich M, et al. Structure and function of the PorB porin from disseminating Neisseria gonorrhoeae. Biochem J 2013; 449:631.</a></li><li><a class="nounderline abstract_t">Ram S, McQuillen DP, Gulati S, et al. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 1998; 188:671.</a></li><li><a class="nounderline abstract_t">Vogel U, Frosch M. Mechanisms of neisserial serum resistance. Mol Microbiol 1999; 32:1133.</a></li><li><a class="nounderline abstract_t">Ngampasutadol J, Ram S, Gulati S, et al. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol 2008; 180:3426.</a></li><li><a class="nounderline abstract_t">Rechner C, Kühlewein C, Müller A, et al. Host glycoprotein Gp96 and scavenger receptor SREC interact with PorB of disseminating Neisseria gonorrhoeae in an epithelial invasion pathway. Cell Host Microbe 2007; 2:393.</a></li><li><a class="nounderline abstract_t">Faulstich M, Böttcher JP, Meyer TF, et al. Pilus phase variation switches gonococcal adherence to invasion by caveolin-1-dependent host cell signaling. PLoS Pathog 2013; 9:e1003373.</a></li><li><a class="nounderline abstract_t">Knapp JS, Holmes KK. Disseminated gonococcal infections caused by Neisseria gonorrhoeae with unique nutritional requirements. J Infect Dis 1975; 132:204.</a></li><li><a class="nounderline abstract_t">Knapp JS, Thornsberry C, Schoolnik GA, et al. Phenotypic and epidemiologic correlates of auxotype in Neisseria gonorrhoeae. J Infect Dis 1978; 138:160.</a></li><li><a class="nounderline abstract_t">Tapsall JW, Phillips EA, Shultz TR, et al. Strain characteristics and antibiotic susceptibility of isolates of Neisseria gonorrhoeae causing disseminated gonococcal infection in Australia. Members of the Australian Gonococcal Surveillance Programme. Int J STD AIDS 1992; 3:273.</a></li><li><a class="nounderline abstract_t">Gutjahr TS, O'Rourke M, Ison CA, Spratt BG. Arginine-, hypoxanthine-, uracil-requiring isolates of Neisseria gonorrhoeae are a clonal lineage with a non-clonal population. Microbiology (Reading) 1997; 143 ( Pt 2):633.</a></li><li><a class="nounderline abstract_t">Sandström EG, Knapp JS, Reller LB, et al. Serogrouping of Neisseria gonorrhoeae: correlation of serogroup with disseminated gonococcal infection. Sex Transm Dis 1984; 11:77.</a></li><li><a class="nounderline abstract_t">Dillard JP, Seifert HS. A variable genetic island specific for Neisseria gonorrhoeae is involved in providing DNA for natural transformation and is found more often in disseminated infection isolates. Mol Microbiol 2001; 41:263.</a></li><li><a class="nounderline abstract_t">Hauck CR, Borisova M, Muenzner P. Exploitation of integrin function by pathogenic microbes. Curr Opin Cell Biol 2012; 24:637.</a></li><li><a class="nounderline abstract_t">Schmitter T, Agerer F, Peterson L, et al. Granulocyte CEACAM3 is a phagocytic receptor of the innate immune system that mediates recognition and elimination of human-specific pathogens. J Exp Med 2004; 199:35.</a></li><li><a class="nounderline abstract_t">Pils S, Gerrard DT, Meyer A, Hauck CR. CEACAM3: an innate immune receptor directed against human-restricted bacterial pathogens. Int J Med Microbiol 2008; 298:553.</a></li><li><a class="nounderline abstract_t">Buntru A, Roth A, Nyffenegger-Jann NJ, Hauck CR. HemITAM signaling by CEACAM3, a human granulocyte receptor recognizing bacterial pathogens. Arch Biochem Biophys 2012; 524:77.</a></li><li><a class="nounderline abstract_t">Roth A, Mattheis C, Muenzner P, et al. Innate recognition by neutrophil granulocytes differs between Neisseria gonorrhoeae strains causing local or disseminating infections. Infect Immun 2013; 81:2358.</a></li><li><a class="nounderline abstract_t">Stein DC, LeVan A, Hardy B, et al. Expression of Opacity Proteins Interferes with the Transmigration of Neisseria gonorrhoeae across Polarized Epithelial Cells. PLoS One 2015; 10:e0134342.</a></li><li><a class="nounderline abstract_t">Lewis LA, Choudhury B, Balthazar JT, et al. Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum. Infect Immun 2009; 77:1112.</a></li><li><a class="nounderline abstract_t">Jonsson AB, Ilver D, Falk P, et al. Sequence changes in the pilus subunit lead to tropism variation of Neisseria gonorrhoeae to human tissue. Mol Microbiol 1994; 13:403.</a></li><li><a class="nounderline abstract_t">Rudel T, van Putten JP, Gibbs CP, et al. Interaction of two variable proteins (PilE and PilC) required for pilus-mediated adherence of Neisseria gonorrhoeae to human epithelial cells. Mol Microbiol 1992; 6:3439.</a></li><li><a class="nounderline abstract_t">Banerjee A, Wang R, Supernavage SL, et al. Implications of phase variation of a gene (pgtA) encoding a pilin galactosyl transferase in gonococcal pathogenesis. J Exp Med 2002; 196:147.</a></li><li><a class="nounderline abstract_t">Power PM, Ku SC, Rutter K, et al. The phase-variable allele of the pilus glycosylation gene pglA is not strongly associated with strains of Neisseria gonorrhoeae isolated from patients with disseminated gonococcal infection. Infect Immun 2007; 75:3202.</a></li><li><a class="nounderline abstract_t">Tronca E, Handsfield HH, Wiesner PJ, Holmes KK. Demonstration of Neisseria gonorrhoeae with fluorescent antibody in patients with disseminated gonococcal infection. J Infect Dis 1974; 129:583.</a></li><li><a class="nounderline abstract_t">Liebling MR, Arkfeld DG, Michelini GA, et al. Identification of Neisseria gonorrhoeae in synovial fluid using the polymerase chain reaction. Arthritis Rheum 1994; 37:702.</a></li><li><a class="nounderline abstract_t">Muralidhar B, Rumore PM, Steinman CR. Use of the polymerase chain reaction to study arthritis due to Neisseria gonorrhoeae. Arthritis Rheum 1994; 37:710.</a></li><li><a class="nounderline abstract_t">Kimmitt PT, Kirby A, Perera N, et al. Identification of Neisseria gonorrhoeae as the causative agent in a case of culture-negative dermatitis-arthritis syndrome using real-time PCR. J Travel Med 2008; 15:369.</a></li><li><a class="nounderline abstract_t">Read P, Abbott R, Pantelidis P, et al. Disseminated gonococcal infection in a homosexual man diagnosed by nucleic acid amplification testing from a skin lesion swab. Sex Transm Infect 2008; 84:348.</a></li><li><a class="nounderline abstract_t">Brandt KD, Cathcart ES, Cohen AS. Gonococcal arthritis. Clinical features correlated with blood, synovial fluid and genitourinary cultures. Arthritis Rheum 1974; 17:503.</a></li><li><a class="nounderline abstract_t">Keiser H, Ruben FL, Wolinsky E, Kushner I. Clinical forms of gonococcal arthritis. N Engl J Med 1968; 279:234.</a></li><li><a class="nounderline abstract_t">Ludivico CL, Myers AR. Survey for immune complexes in disseminated gonococcal arthritis-dermatitis syndrome. Arthritis Rheum 1979; 22:19.</a></li><li><a class="nounderline abstract_t">Walker LC, Ahlin TD, Tung KS, Williams RC Jr. Circulating immune complexes in disseminated gonorrheal infection. Ann Intern Med 1978; 89:28.</a></li><li><a class="nounderline abstract_t">Manicourt DH, Orloff S. Gonococcal arthritis-dermatitis syndrome. Study of serum and synovial fluid immune complex levels. Arthritis Rheum 1982; 25:574.</a></li><li><a class="nounderline abstract_t">Fleming TJ, Wallsmith DE, Rosenthal RS. Arthropathic properties of gonococcal peptidoglycan fragments: implications for the pathogenesis of disseminated gonococcal disease. Infect Immun 1986; 52:600.</a></li><li><a class="nounderline abstract_t">Fisette PL, Ram S, Andersen JM, et al. The Lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-kappaB activation in epithelial cells in a Toll-like receptor 2-dependent manner. J Biol Chem 2003; 278:46252.</a></li><li><a class="nounderline abstract_t">Gelfand SG, Masi AT, Garcia-Kutzbach A. Spectrum of gonococcal arthritis: evidence for sequential stages and clinical subgroups. J Rheumatol 1975; 2:83.</a></li><li><a class="nounderline abstract_t">Akkinepally S, Douglass E, Moreno A. Tricuspid valve gonococcal endocarditis: fourth case report. Int J Infect Dis 2010; 14 Suppl 3:e196.</a></li><li><a class="nounderline abstract_t">Nielsen US, Knudsen JB, Pedersen LN, Møller JK. Neisseria gonorrhoeae endocarditis confirmed by nucleic acid amplification assays performed on aortic valve tissue. J Clin Microbiol 2009; 47:865.</a></li><li><a class="nounderline abstract_t">Bunker D, Kerr LD. Acute Myopericarditis Likely Secondary to Disseminated Gonococcal Infection. Case Rep Infect Dis 2015; 2015:385126.</a></li><li><a class="nounderline abstract_t">Mofredj A, Baraka D, Madec Y, Lemaitre P. Disseminated gonococcal infection and meningitis. Am J Med 2000; 109:71.</a></li><li><a class="nounderline abstract_t">Del Rio C, Stephens DS, Knapp JS, et al. Comparison of isolates of Neisseria gonorrhoeae causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency. J Clin Microbiol 1989; 27:1045.</a></li><li><a class="nounderline abstract_t">Shibata Y, Kumano T, Shinoda T, et al. Gonococcal osteomyelitis of the shoulder extended from gonococcal arthritis: diagnosis by a polymerase chain reaction assay. J Shoulder Elbow Surg 2004; 13:467.</a></li><li><a class="nounderline abstract_t">van Hal SJ, Post JJ. An unusual cause of an epidural abscess. Med J Aust 2004; 180:40.</a></li><li><a class="nounderline abstract_t">Viani RM, Bromberg K, Bradley JS. Obturator internus muscle abscess in children: report of seven cases and review. Clin Infect Dis 1999; 28:117.</a></li><li><a class="nounderline abstract_t">Jain S, Win HN, Chalam V, Yee L. Disseminated gonococcal infection presenting as vasculitis: a case report. J Clin Pathol 2007; 60:90.</a></li><li><a class="nounderline abstract_t">English JC, Monk JS. Gonococcal dermatitis-arthritis syndrome. Am Fam Physician 1986; 34:77.</a></li><li><a class="nounderline abstract_t">García-De La Torre I, Nava-Zavala A. Gonococcal and nongonococcal arthritis. Rheum Dis Clin North Am 2009; 35:63.</a></li><li><a class="nounderline abstract_t">Beatrous SV, Grisoli SB, Riahi RR, et al. Cutaneous manifestations of disseminated gonococcemia. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Yadav A, Nazeer SR, Wainscott MP, Miller AH. Shoulder pain: a presentation of bilateral gonococcal arthritis of the shoulders. J Emerg Med 2009; 36:19.</a></li><li><a class="nounderline abstract_t">Craig JG, van Holsbeeck M, Alva M. Gonococcal arthritis of the shoulder and septic extensor tenosynovitis of the wrist: sonographic appearances. J Ultrasound Med 2003; 22:221.</a></li><li><a class="nounderline abstract_t">Guillot X, Delattre E, Prati C, Wendling D. Destructive septic arthritis of the sternoclavicular joint due to Neisseria gonorrhoeae. Joint Bone Spine 2012; 79:519.</a></li><li><a class="nounderline abstract_t">El Mezouar I, Tahiri L, Lazrak F, et al. Gonococcal polyarthritis with sternoclavicular joint involvement in pregnant woman: a case report. Pan Afr Med J 2014; 17:242.</a></li><li><a class="nounderline abstract_t">Mesa JJ, Lin SS, Catalano J, Deutch LS. Sternoclavicular gonococcal arthritis in an adolescent girl. Orthopedics 1998; 21:87.</a></li><li><a class="nounderline abstract_t">Hagiya H, Onishi N, Ebara H, et al. Disseminated gonococcal infection in an elderly Japanese man. Intern Med 2013; 52:2669.</a></li><li><a class="nounderline abstract_t">Al-Suleiman SA, Grimes EM, Jonas HS. Disseminated gonococcal infections. Obstet Gynecol 1983; 61:48.</a></li><li><a class="nounderline abstract_t">Holmes KK, Counts GW, Beaty HN. Disseminated gonococcal infection. Ann Intern Med 1971; 74:979.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep 2014; 63:1.</a></li><li><a class="nounderline abstract_t">Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002; 15:527.</a></li><li><a class="nounderline abstract_t">Visser S, Tupper J. Septic until proven otherwise: approach to and treatment of the septic joint in adult patients. Can Fam Physician 2009; 55:374.</a></li><li><a class="nounderline abstract_t">Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial fluid tests. What should be ordered? JAMA 1990; 264:1009.</a></li><li><a class="nounderline abstract_t">Rompalo AM, Hook EW 3rd, Roberts PL, et al. The acute arthritis-dermatitis syndrome. The changing importance of Neisseria gonorrhoeae and Neisseria meningitidis. Arch Intern Med 1987; 147:281.</a></li><li><a class="nounderline abstract_t">Andersson S, Krook A. Primary meningococcal arthritis. Scand J Infect Dis 1987; 19:51.</a></li><li><a class="nounderline abstract_t">Cabellos C, Nolla JM, Verdaguer R, et al. Arthritis related to systemic meningococcal disease: 34 years' experience. Eur J Clin Microbiol Infect Dis 2012; 31:2661.</a></li><li><a class="nounderline abstract_t">Maroñas-Jiménez L, Menis D, Delgado-Márquez AM, et al. Primary herpes simplex infection with genital and extra-genital lesions mimicking disseminated gonococcal disease. Br J Dermatol 2015; 172:278.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Updated case-finding guidance: monkeypox outbreak—United States, 2022 https://emergency.cdc.gov/han/2022/han00468.asp?ACSTrackingID=USCDC_511-DM84268&amp;ACSTrackingLabel=HAN%20465%20-%20General%20Public&amp;deliveryName=USCDC_511-DM84268 (Accessed on June 16, 2022).</li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Rinaldi RZ, Harrison WO, Fan PT. Penicillin-resistant gonococcal arthritis. A report of four cases. Ann Intern Med 1982; 97:43.</a></li><li><a class="nounderline abstract_t">Mirmiran R, Hembree JL 3rd, Reed WP, Jessup D. Disseminated gonococcal infection: a case of beta-lactamase-producing Neisseria gonorrhoeae. J Am Podiatr Med Assoc 2000; 90:273.</a></li><li><a class="nounderline abstract_t">Dal Conte I, Starnino S, Di Perri G, Stefanelli P. Disseminated gonococcal infection in an immunocompetent patient caused by an imported Neisseria gonorrhoeae multidrug-resistant strain. J Clin Microbiol 2006; 44:3833.</a></li><li><a class="nounderline abstract_t">Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009; 10:555.</a></li><li><a class="nounderline abstract_t">Yin YP, Han Y, Dai XQ, et al. Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016. PLoS Med 2018; 15:e1002499.</a></li><li><a class="nounderline abstract_t">Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163.</a></li><li><a class="nounderline abstract_t">St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1911.</a></li></ol></div><div id="topicVersionRevision">Topic 7603 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5101355" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Septic gonococcal dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25792538" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The epidemiology of gonococcal arthritis in an Indigenous Australian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6431620" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence of disseminated gonococcal infection correlated with the presence of AHU auxotype of Neisseria gonorrhoeae in a community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23920397" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22353959" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Disseminated gonococcal infection in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787521" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gonococcal arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133965" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : HIV infection as a risk factor for septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25212090" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The rarity of gonococcal arthritis in association with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826910" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gonococcal arthritis in human immunodeficiency virus-infected patients. Review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906073" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Septic arthritis in patients with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25953962" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gonococcal tenosynovitis in two HIV-infected heterosexual men: delayed diagnoses following negative urine nucleic acid amplification testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26362744" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Septic arthritis in immunocompetent and immunosuppressed hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8689280" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Peripheral pyogenic arthritis. A study of one hundred seventy-nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133971" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bacterial joint infections in England and Wales: analysis of bacterial isolates over a four year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153550" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The outcome of bacterial arthritis: a prospective community-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895378" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Musculoskeletal infections in intravenous drug addicts: report of 34 cases with analysis of microbiological aspects and pathogenic mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2116207" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Septic gonococcal arthritis is much more common in the USA than in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6415361" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2860565" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gonococcal infection: a model of molecular pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/415007" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Studies on gonococcus infection. XIII. Occurrence of color/opacity colonial variants in clinical cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/120407" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Variations in surface protein composition associated with virulence properties in opacity types of Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7468687" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : In vitro modeling of acute salpingitis caused by Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297736" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gonococcal arthritis (disseminated gonococcal infection).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6792081" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ability of Neisseria gonorrhoeae, Neisseria meningitidis, and commensal Neisseria species to obtain iron from transferrin and iron compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16753698" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Gonorrhoea infection presenting in pregnancy with septic arthritis of the sternoclavicular joint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018507" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Disseminated gonococcal infection in pregnancy presenting as meningitis and dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16136359" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Disseminated gonococcal infection during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19697211" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disseminated gonococcal infection in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/109025" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2830678" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Underlying complement deficiency in patients with disseminated gonococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777471" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chronic gonococcal arthritis with C5 deficiency presenting with brief flare-ups: case study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993152" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gonococcal arthritis in an era of increasing penicillin resistance. Presentations and outcomes in 41 recent cases (1985-1991).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2287942" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Increased risk of neisserial infections in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110148" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Complement and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6433145" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24113196" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gonococcemia mimicking a lupus flare in a young woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23922248" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Polyarthritis in a 19-year-old female with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581812" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Disseminated gonococcal infection and eculizumab--a "high risk" connection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511000" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Gonococcal septic shock associated with eculizumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418536" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3088132" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Auxotypes, penicillin susceptibility, and serogroups of Neisseria gonorrhoeae from disseminated and uncomplicated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157049" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790801" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Low-phosphate-dependent invasion resembles a general way for Neisseria gonorrhoeae to enter host cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095086" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Structure and function of the PorB porin from disseminating Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9705949" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383755" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mechanisms of neisserial serum resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18292569" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18078691" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Host glycoprotein Gp96 and scavenger receptor SREC interact with PorB of disseminating Neisseria gonorrhoeae in an epithelial invasion pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23717204" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pilus phase variation switches gonococcal adherence to invasion by caveolin-1-dependent host cell signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/125773" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Disseminated gonococcal infections caused by Neisseria gonorrhoeae with unique nutritional requirements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/98600" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Phenotypic and epidemiologic correlates of auxotype in Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1504159" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Strain characteristics and antibiotic susceptibility of isolates of Neisseria gonorrhoeae causing disseminated gonococcal infection in Australia. Members of the Australian Gonococcal Surveillance Programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043139" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Arginine-, hypoxanthine-, uracil-requiring isolates of Neisseria gonorrhoeae are a clonal lineage with a non-clonal population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6431621" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Serogrouping of Neisseria gonorrhoeae: correlation of serogroup with disseminated gonococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454218" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A variable genetic island specific for Neisseria gonorrhoeae is involved in providing DNA for natural transformation and is found more often in disseminated infection isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22884865" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Exploitation of integrin function by pathogenic microbes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14707113" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Granulocyte CEACAM3 is a phagocytic receptor of the innate immune system that mediates recognition and elimination of human-specific pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606569" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CEACAM3: an innate immune receptor directed against human-restricted bacterial pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22469950" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : HemITAM signaling by CEACAM3, a human granulocyte receptor recognizing bacterial pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23630956" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Innate recognition by neutrophil granulocytes differs between Neisseria gonorrhoeae strains causing local or disseminating infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244560" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Expression of Opacity Proteins Interferes with the Transmigration of Neisseria gonorrhoeae across Polarized Epithelial Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114544" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7997158" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sequence changes in the pilus subunit lead to tropism variation of Neisseria gonorrhoeae to human tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1362447" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Interaction of two variable proteins (PilE and PilC) required for pilus-mediated adherence of Neisseria gonorrhoeae to human epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12119340" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Implications of phase variation of a gene (pgtA) encoding a pilin galactosyl transferase in gonococcal pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296763" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The phase-variable allele of the pilus glycosylation gene pglA is not strongly associated with strains of Neisseria gonorrhoeae isolated from patients with disseminated gonococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4207310" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Demonstration of Neisseria gonorrhoeae with fluorescent antibody in patients with disseminated gonococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8185697" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Identification of Neisseria gonorrhoeae in synovial fluid using the polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8185698" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Use of the polymerase chain reaction to study arthritis due to Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006515" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Identification of Neisseria gonorrhoeae as the causative agent in a case of culture-negative dermatitis-arthritis syndrome using real-time PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809698" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Disseminated gonococcal infection in a homosexual man diagnosed by nucleic acid amplification testing from a skin lesion swab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4213129" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Gonococcal arthritis. Clinical features correlated with blood, synovial fluid and genitourinary cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4969531" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical forms of gonococcal arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/153144" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Survey for immune complexes in disseminated gonococcal arthritis-dermatitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/666182" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Circulating immune complexes in disseminated gonorrheal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7082402" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Gonococcal arthritis-dermatitis syndrome. Study of serum and synovial fluid immune complex levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3084386" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Arthropathic properties of gonococcal peptidoglycan fragments: implications for the pathogenesis of disseminated gonococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966099" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The Lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-kappaB activation in epithelial cells in a Toll-like receptor 2-dependent manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1185739" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Spectrum of gonococcal arthritis: evidence for sequential stages and clinical subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19900829" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Tricuspid valve gonococcal endocarditis: fourth case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109481" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Neisseria gonorrhoeae endocarditis confirmed by nucleic acid amplification assays performed on aortic valve tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26246922" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Acute Myopericarditis Likely Secondary to Disseminated Gonococcal Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10991742" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Disseminated gonococcal infection and meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2473091" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Comparison of isolates of Neisseria gonorrhoeae causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220891" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Gonococcal osteomyelitis of the shoulder extended from gonococcal arthritis: diagnosis by a polymerase chain reaction assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14709128" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : An unusual cause of an epidural abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028081" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Obturator internus muscle abscess in children: report of seven cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213353" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Disseminated gonococcal infection presenting as vasculitis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3728263" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Gonococcal dermatitis-arthritis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480997" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Gonococcal and nongonococcal arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329470" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cutaneous manifestations of disseminated gonococcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976773" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Shoulder pain: a presentation of bilateral gonococcal arthritis of the shoulders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12562127" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Gonococcal arthritis of the shoulder and septic extensor tenosynovitis of the wrist: sonographic appearances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503167" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Destructive septic arthritis of the sternoclavicular joint due to Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170386" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Gonococcal polyarthritis with sternoclavicular joint involvement in pregnant woman: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9474637" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Sternoclavicular gonococcal arthritis in an adolescent girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24292761" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Disseminated gonococcal infection in an elderly Japanese man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6681667" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Disseminated gonococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4996345" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Disseminated gonococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24622331" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364368" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Acute septic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19366944" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Septic until proven otherwise: approach to and treatment of the septic joint in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2198352" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Synovial fluid tests. What should be ordered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3101626" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The acute arthritis-dermatitis syndrome. The changing importance of Neisseria gonorrhoeae and Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3563427" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Primary meningococcal arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22476361" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Arthritis related to systemic meningococcal disease: 34 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24930808" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Primary herpes simplex infection with genital and extra-genital lesions mimicking disseminated gonococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24930808" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Primary herpes simplex infection with genital and extra-genital lesions mimicking disseminated gonococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807166" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Penicillin-resistant gonococcal arthritis. A report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10833879" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Disseminated gonococcal infection: a case of beta-lactamase-producing Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021122" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Disseminated gonococcal infection in an immunocompetent patient caused by an imported Neisseria gonorrhoeae multidrug-resistant strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19284360" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The use of cephalosporins for gonorrhea: the impending problem of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29408881" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: A retrospective study of national surveillance data from 2013 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23299608" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332296" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
